Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

To evaluate the long‐term safety of rituximab in an observational cohort of patients with rheumatoid arthritis (RA) who had an inadequate response to ≥1 anti–tumor necrosis factor therapy in the US (SUNSTONE [Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti‐TNF Therapy] registry).

R. Marcus | D. Furst | K. Dao | N. Stahl | J. Levine | K. Saag | M. Arora | P. Rocca | C. Hakim | K. Winthrop | D. Tabechian | A. Chauhan | M. Greenwald | A. Jahreis | S. Songcharoen | M. Abeles | C. Dugowson | M. Feinman | M. Bognár | P. Schneider | A. Singhal | C. Neuwelt | A. Braun | H. Krug | A. John | T. Haselkorn | D. Sikes | K. Stark | S. Golombek | S. Lakhanpal | J. Kim | R. Diegel | M. Cascino | J. Anderson | H. El-Kadi | W. Rizzo | A. Anand | S. Schwartzman | Y. Lee | J. Mossell | P. Nguyen | R. Venuturupalli | R. Lidman | C. Danning | D. Hallegua | L. Peterson | A. Ahmed | R. Pittsley | B. Zamiri | T. Lang | K. Colburn | J. Pei | C. Knee | F. Murphy | L. Brent | W. Shergy | D. Ridley | K. Kolba | D. Bacha | I. Diab | D. Weiss | A. Fischer | H. Blumstein | N. Carteron | M. Penmetcha | A. Bohan | A. Askari | A. Nami | R. Keating | A. Sankoorikal | A. Snyder | D. Conaway | A. Fraser | C. Mehta | J. Nascimento | G. Roane | C. Scoville | K. Oelke | J. Alper | M. Fondal | M. Borofsky | S. Metyas | K. Han | A. Eggebeen | D. Klashman | E. Zable | P. Saway | M. Toth | M. Rezaian | W. Lee | J. Udell | R. Moidel | J. Alloway | J. Feinstein | M. Rosen | S. Fraser | H. Feinberg | W. Shiel | M. Abdulky | H. Adelglass | S. Baca | S. Bagheri | S. Ballou | R. Bennett | L. Bidula | C. Boniske | E. Box | T. Brennan | I. Cabalar | K. Chaudhary | M. Cima | A. Cochinwala | H. Cohen | J. Dean | R. Ditzian-Kadanoff | J. Dowd | B. Foad | P. Freeman | M. Garber | A. Goldstein | N. Greenstein | J. Halla | B. Harris | H. Hauptman | J. Hirsh | M. Hoffman | J. Huntwork | M. Husni | F. Hyer | R. Hymowitz | R. Jones | S. Kanagasegar | J. Kappes | G. Kelly | C. King | G. Krick | U. Kumar | S. Lauter | T. Lawrence Ford | J. Leisen | J. Lipstate | J. Malinak | D. Martin | G. Melton | K. Miller | C. Moore | G. Muñoz | N. Neal | R. Neiman | M. Niemer | M. Oza | S. Pachaidee | S. Patel | S. Pegram | J. Perkins | A. Perl | K. Portnoff | D. Rahmani | N. Raja | W. Ratnoff | C. Rhea | D. Rice | A. Rivadeneira | W. Saikali | M. Saitta | R. Shurmur | M. Sosenko | O. Soto Raices | M. Strachan | A. Stupi | N. Sullivan | R. Sylvester | C. Tagoe | P. Taylor | S. Thakker | M. Thakor | N. Thakur | W. Tidmore | D. Trostle | M. J. van de Stouwe | K. Weselman | D. Winn | C. Yung | W. Lee | B. Harris | J. Kim | M. Bognár

[1]  J. Galloway,et al.  Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis , 2018, Rheumatology.

[2]  J. Greenberg,et al.  SAT0196 Repeated rituximab infusions for the therapy of rheumatoid arthritis is not associated with increased rates of serious infections , 2017 .

[3]  W. Dixon,et al.  The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis , 2016, Rheumatology.

[4]  D. Furst,et al.  Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years , 2015, The Journal of Rheumatology.

[5]  P. Polgreen,et al.  Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance , 2015, Annals of the rheumatic diseases.

[6]  J. Kremer,et al.  Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry , 2015, Arthritis Research & Therapy.

[7]  M. Hochberg,et al.  Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis , 2015, Arthritis Research & Therapy.

[8]  J. Lewis,et al.  Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare , 2015, Arthritis & rheumatology.

[9]  D. Furst,et al.  Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients , 2012, Annals of the rheumatic diseases.

[10]  Hyon K. Choi,et al.  The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study , 2012, Annals of the rheumatic diseases.

[11]  M. Eveslage,et al.  Extended Report , 2011 .

[12]  P. Tak,et al.  Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial , 2010, Annals of the rheumatic diseases.

[13]  B Combe,et al.  Extended Report , 2022 .

[14]  P. Tak,et al.  Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) , 2010, Rheumatology.

[15]  S. Agarwal,et al.  Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial , 2010, The Journal of Rheumatology.

[16]  D. Furst,et al.  Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials , 2010 .

[17]  Hyon K. Choi,et al.  The risk of hospitalized infection in patients with rheumatoid arthritis. , 2008, The Journal of rheumatology.

[18]  W. Dixon,et al.  The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis , 2008, Current opinion in rheumatology.

[19]  M. Dougados,et al.  Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. , 2007, Arthritis and rheumatism.

[20]  F. Wolfe,et al.  Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. , 2007, Arthritis and rheumatism.

[21]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[22]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[23]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[24]  A. Iliadou,et al.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[25]  G. Burmester,et al.  Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[26]  Richard W. Martin,et al.  Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. , 2005, The Journal of rheumatology.

[27]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[28]  P. Lipsky,et al.  Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. , 2004, Arthritis and rheumatism.

[29]  F. Wolfe,et al.  Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. , 2004, The American journal of medicine.

[30]  S. Gabriel,et al.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.

[31]  J. Listing,et al.  The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. , 2013, Rheumatology.

[32]  S. Agarwal,et al.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. , 2010, Arthritis and rheumatism.